adoption is supported by both targeted commercialization efforts such as the launch of RenovoRx's sales and marketing team in late 2025 and the growing body of real-world clinical evidence regarding the safety and effectiveness of RenovoCath in patients with solid tumors. Si

May 14, 2026 / receipt

Research and development expenses were 1.7 million for the quarter, up from 1.3 million in the first quarter of 2024. This $0.4 million increase was primarily driven by the following, higher employee compensation due to cost of living adjustments, increased manufacturing and non-recurring engineering costs to support commercial scale-up, greater participation in conferences and trade shows, and other ongoing R&D activities.

May 15, 2025 / receipt, needs a key / Ron Kozak, VP controller and principal accounting o | earnings call 2025-05-15 | transcript 952c4e6b-9ae9-4e95-a1c3-271be92d26b9 | chars 12160-12587 | segment 12

Broadening adoption momentum: Customer pipeline continues to expand across high-volume NCI-designated centers, academic institutions, and large community centers.

ir_statement / Sep 16, 2026 / receipt

Deployed a focused and agile sales and marketing team in late 2025 with strong understanding of the market and a clear strategy.

ir_statement / Sep 16, 2026 / receipt

Executed within the existing operating budget to support growth in 2026 and beyond.

ir_statement / Sep 16, 2026 / receipt

First full year of commercialization (achieved without dedicated sales and marketing infrastructure to conserve cash during majority of 2025).

ir_statement / Sep 16, 2026 / receipt

RenovoCath Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization with Focused and Agile Sales and Marketing Team

ir_statement / Sep 16, 2026 / receipt

Establishment of focused and agile commercial team in late 2025

ir_statement / Sep 16, 2026 / receipt

Revenue range of $3-4M

ir_statement / Sep 16, 2026 / receipt

Targeting 36 active commercial sites by year end, more than double current footprint of 16 active sites

ir_statement / Sep 16, 2026 / receipt

16 cancer centers are utilizing RenovoCath with a robust pipeline of 32 additional centers in various stages of evaluation, approval, and onboarding

ir_statement / Sep 16, 2026 / receipt

In Q4 2025, completed initial buildout of commercial infrastructure supported by a focused and agile sales and marketing team

ir_statement / Sep 16, 2026 / receipt

Targeting 36 active commercial cancer centers by year end

ir_statement / Sep 16, 2026 / receipt

Broadening adoption momentum: Customer pipeline continues to expand across high-volume NCI-designated centers, academic institutions, and large community centers.

ir_statement / Sep 16, 2026 / receipt